This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This research plan relates to the preclinical development of antibodies capable of neutralizing staphylococcal enterotoxin B (SEB) in vivo. The ultimate objective of this proposal is to prepare for submission of an IND to the FDA for the clinical development of Human Anti-SEB MAbs (HASMs). Morphotek has identified at least two HASMs that can block SEB activity in vivo.
The aims of this proposal address all the requirements for an IND submission including but not limited to: justification and rationale of the proposed therapeutic approach;efficacy in animal models;toxicology and safety parameters of our antibodies(s);chemistry, manufacturing and controls (CMC) section;design of clinical protocol. There is considerable need to develop vaccines and therapeutic strategies capable of preventing or reversing SEB toxicity. The humanized monoclonal antibody MORAb-048 has shown in vitro and in vivo (rodent models) to be specific to and neutralize SEB. This antibody was further evaluated in a nonhuman primate aerosol model of SEB intoxication. An initial pharmacokinetic profile of MORAb-048 indicated plasma levels peaked at approximately 48 hours after injection. Thereafter, MORAb-048 was administered prophylactically and animals were then exposed to either three or nine times the 50% lethal dose of purified SEB by small particle aerosol. Results indicated that MORAb-048 completely protected (100% survival) animals from SEB-induced lethality at the lower challenge dose (3x LD^50) and partially protected (83% survival) at the higher challenge dose (9x LD^50). Groups administered MORAb-048 appeared to experience a lower rate of clinical/enteric effects than unprotected animals. Collectively, these results show that MORAb-048 protects rhesus macaques from SEB-induced intoxication and there is a dose-limiting effect based upon an escalating challenge used in the study.
|Mahalingam, Ravi; Kaufer, Benedikt B; Ouwendijk, Werner J D et al. (2018) Attenuation of Simian Varicella Virus Infection by Enhanced Green Fluorescent Protein in Rhesus Macaques. J Virol 92:|
|Kumar, Vinay; Mansfield, Joshua; Fan, Rong et al. (2018) miR-130a and miR-212 Disrupt the Intestinal Epithelial Barrier through Modulation of PPAR? and Occludin Expression in Chronic Simian Immunodeficiency Virus-Infected Rhesus Macaques. J Immunol 200:2677-2689|
|Parthasarathy, Geetha; Philipp, Mario T (2018) Intracellular TLR7 is activated in human oligodendrocytes in response to Borrelia burgdorferi exposure. Neurosci Lett 671:38-42|
|McNamara, Ryan P; Costantini, Lindsey M; Myers, T Alix et al. (2018) Nef Secretion into Extracellular Vesicles or Exosomes Is Conserved across Human and Simian Immunodeficiency Viruses. MBio 9:|
|Calenda, Giulia; Villegas, Guillermo; Barnable, Patrick et al. (2017) MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa. J Acquir Immune Defic Syndr 74:e67-e74|
|Datta, Dibyadyuti; Bansal, Geetha P; Grasperge, Brooke et al. (2017) Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques. Vaccine 35:7049-7056|
|Yi, Fei; Guo, Jia; Dabbagh, Deemah et al. (2017) Discovery of Novel Small-Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1. J Virol 91:|
|Jorgensen, Matthew J; Lambert, Kelsey R; Breaux, Sarah D et al. (2017) Pair housing of Vervets/African Green Monkeys for biomedical research. Am J Primatol 79:1-10|
|Ramesh, Geeta; Martinez, Alejandra N; Martin, Dale S et al. (2017) Effects of dexamethasone and meloxicam on Borrelia burgdorferi-induced inflammation in glial and neuronal cells of the central nervous system. J Neuroinflammation 14:28|
|Parthasarathy, Geetha; Philipp, Mario T (2017) Receptor tyrosine kinases play a significant role in human oligodendrocyte inflammation and cell death associated with the Lyme disease bacterium Borrelia burgdorferi. J Neuroinflammation 14:110|
Showing the most recent 10 out of 352 publications